SCHEMBL3530393

SCHEMBL3530393

Cc1cc(=O)n(C)n1-c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.72
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 2/20 0.49
BCHE P06276 1/20 0.49
PTGS2 P35354 1/20 0.49
LMNA P02545 2/20 0.47
ADORA3 P0DMS8 1/20 0.47
TSHR P16473 3/20 0.46
CYP1A2 P05177 2/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 2/20 0.42
CYP2D6 P10635 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Antipyrine SCHEMBL20452 0.84 NAPRT (1.00) NAPRTALDH1A1ALOX15BCHEPTGS2
SCHEMBL5426155 0.83 NAPRT (0.71) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL28445203 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL28220175 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL28183108 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL8995343 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL8736656 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL9845605 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL18260589 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2
Antipyrine SCHEMBL7020007 0.82 NAPRT (0.96) NAPRTALDH1A1ALOX15BCHEPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 NAPRT 2057/4885ALDH1A1 105/4885ALOX15 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.